evaluate the pharmaceuticals company wegovy on glp-1 efficacy / effectiveness Information Survey: More Than Half of Respondents Take a Compare GLP-1 Options | Ozempic

135 million obese Indians

Retatrutide could become the biggest drug in history

See how Hims, Ro, Calibrate, Mochi Health, and Meto compare on lab requirements, specialist access, monitoring cadence, and insurance coverage before you enrol.

GLP-1s account for 23% of first line diabetes therapy in 2025 up from 3% in 2021 Since 2019, the American Diabetes Association (ADA) has revised its Standards of Care each year to expand the role of GLP-1 receptor agonists and SGLT2 inhibitors as first-line treatments for T2D2

The class of drugs, which includes Novo Nordisks Ozempic and Wegovy, are associated with the risk of gastrointestinal adverse events when used for weight loss, finds a study published Thursday in JAMA.

Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.